相似文献
1
Drug treatment of multiple sclerosis. Clinical review was unsystematic.
BMJ. 2001 Feb 3;322(7281):299.
2
Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.
3
Interferon-beta 1b: new hope for multiple sclerosis.
Nurse Pract. 1994 Jan;19(1):6.
4
All people with MS have a right to be treated.
Br J Nurs. 2000;9(13):816. doi: 10.12968/bjon.2000.9.13.5506.
5
[Interferon-beta in the treatment of multiple sclerosis].
Duodecim. 1995;111(7):587-9.
6
[A short history of beta-interferon therapy of multiple sclerosis].
Med Klin (Munich). 2001 Sep 15;96 Suppl 1:3-9.
7
Funding medicines for people with multiple sclerosis.
BMJ. 2001 Dec 15;323(7326):1379-80. doi: 10.1136/bmj.323.7326.1379.
8
[Place of residence determines access to interferon-beta therapy in MS. Less than 15 per cent of patients are treated--big differences between the counties].
Lakartidningen. 1999 Dec 8;96(49):5492-5.
9
Multiple sclerosis drug prompts rationing fears.
BMJ. 1995 Oct 14;311(7011):969. doi: 10.1136/bmj.311.7011.969.
10
[Interferon-beta in multiple sclerosis--who is going to be treated?].
Tidsskr Nor Laegeforen. 1999 Sep 10;119(21):3114.
本文引用的文献
1
Drug treatment of multiple sclerosis.
BMJ. 2000;321(7259):490-4. doi: 10.1136/bmj.321.7259.490.
2
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Health Technol Assess. 2000;4(9):i-iv, 1-101.
3
Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.
4
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
Lancet. 1999 Mar 20;353(9157):964-9. doi: 10.1016/s0140-6736(98)03053-0.
Zotero 插件